» Articles » PMID: 35676734

Longitudinal Evaluation of Neuroinflammation and Oxidative Stress in a Mouse Model of Alzheimer Disease Using Positron Emission Tomography

Abstract

Background: Validation of new biomarkers of Alzheimer disease (AD) is crucial for the successful development and implementation of treatment strategies. Additional to traditional AT(N) biomarkers, neuroinflammation biomarkers, such as translocator protein (TSPO) and cystine/glutamine antiporter system (x), could be considered when assessing AD progression. Herein, we report the longitudinal investigation of [F]DPA-714 and [F]FSPG for their ability to detect TSPO and x biomarkers, respectively, in the 5xFAD mouse model for AD.

Methods: Expression of TSPO and x system was assessed longitudinally (2-12 months of age) on 5xFAD mice and their respective controls by positron emission tomography (PET) imaging using radioligands [F]DPA-714 and [F]FSPG. In parallel, in the same mice, amyloid-β plaque deposition was assessed with the amyloid PET radiotracer [F]florbetaben. In vivo findings were correlated to ex vivo immunofluorescence staining of TSPO and x in microglia/macrophages and astrocytes on brain slices. Physiological changes of the brain tissue were assessed by magnetic resonance imaging (MRI) in 12-month-old mice.

Results: PET studies showed a significant increase in the uptake of [F]DPA-714 and [F]FSPG in the cortex, hippocampus, and thalamus in 5xFAD but not in WT mice over time. The results correlate with Aβ plaque deposition. Ex vivo staining confirmed higher TSPO overexpression in both, microglia/macrophages and astrocytes, and overexpression of x in non-glial cells of 5xFAD mice. Additionally, the results show that Aβ plaques were surrounded by microglia/macrophages overexpressing TSPO. MRI studies showed significant tissue shrinkage and microstructural alterations in 5xFAD mice compared to controls.

Conclusions: TSPO and x overexpression can be assessed by [F]DPA-714 and [F]FSPG, respectively, and correlate with the level of Aβ plaque deposition obtained with a PET amyloid tracer. These results position the two tracers as promising imaging tools for the evaluation of disease progression. Longitudinal in vivo study in the 5xFAD mouse model shows that TSPO and oxidative stress assessment through [F]DPA-714 and [F]FSPG-PET imaging, respectively, could serve as a potential tool for the evaluation of Alzheimer disease progression.

Citing Articles

The neural basis of neuropsychiatric symptoms in Alzheimer's disease.

Zhang N, Zhang S, Zhang L, Tao H, Zhang G Front Aging Neurosci. 2024; 16:1487875.

PMID: 39703925 PMC: 11655510. DOI: 10.3389/fnagi.2024.1487875.


Exploring the anti-inflammatory effects of curcumin encapsulated within ferritin nanocages: a comprehensive in vivo and in vitro study in Alzheimer's disease.

Morasso C, Truffi M, Tinelli V, Stivaktakis P, Di Gerlando R, Francesca D J Nanobiotechnology. 2024; 22(1):718.

PMID: 39551771 PMC: 11571668. DOI: 10.1186/s12951-024-02897-4.


Palmitoyl-L-carnitine induces tau phosphorylation and mitochondrial dysfunction in neuronal cells.

Yoon G, Kam M, Koh Y, Jo C PLoS One. 2024; 19(11):e0313507.

PMID: 39536002 PMC: 11560007. DOI: 10.1371/journal.pone.0313507.


NAD-boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer's disease via ATF4-dependent mitochondrial UPR.

Xiong X, Hou J, Zheng Y, Jiang T, Zhao X, Cai J Cell Death Dis. 2024; 15(10):744.

PMID: 39394148 PMC: 11470026. DOI: 10.1038/s41419-024-07062-1.


Exploring Potential Mechanisms Accounting for Iron Accumulation in the Central Nervous System of Patients with Alzheimer's Disease.

Levine S Cells. 2024; 13(8.

PMID: 38667304 PMC: 11049304. DOI: 10.3390/cells13080689.


References
1.
Zaragoza R . Transport of Amino Acids Across the Blood-Brain Barrier. Front Physiol. 2020; 11:973. PMC: 7538855. DOI: 10.3389/fphys.2020.00973. View

2.
Selkoe D, Hardy J . The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8(6):595-608. PMC: 4888851. DOI: 10.15252/emmm.201606210. View

3.
Kreisl W, Kim M, Coughlin J, Henter I, Owen D, Innis R . PET imaging of neuroinflammation in neurological disorders. Lancet Neurol. 2020; 19(11):940-950. PMC: 7912433. DOI: 10.1016/S1474-4422(20)30346-X. View

4.
Dunn B, Stein P, Cavazzoni P . Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective. JAMA Intern Med. 2021; 181(10):1276-1278. DOI: 10.1001/jamainternmed.2021.4607. View

5.
Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F . Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 2017; 14:450-464. PMC: 5680523. DOI: 10.1016/j.redox.2017.10.014. View